CytomX Therapeutics, Inc.

DB:6C1 Stock Report

Market Cap: €103.5m

CytomX Therapeutics Future Growth

Future criteria checks 0/6

CytomX Therapeutics's revenue and earnings are forecast to decline at 13.3% and 29.6% per annum respectively. EPS is expected to decline by 20.3% per annum. Return on equity is forecast to be -177.5% in 3 years.

Key information

-29.6%

Earnings growth rate

-20.3%

EPS growth rate

Biotechs earnings growth31.5%
Revenue growth rate-13.3%
Future return on equity-177.5%
Analyst coverage

Good

Last updated22 Apr 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

DB:6C1 - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202646-71-13N/A3
12/31/202573-43-56-796
12/31/202494-24-52-285
12/31/2023101-1-57-56N/A
9/30/202395-10-36-35N/A
6/30/202379-42-52-51N/A
3/31/202368-71-61-60N/A
12/31/202253-99-113-111N/A
9/30/202221-149-142-141N/A
6/30/202227-143-138-136N/A
3/31/202230-132-132-130N/A
12/31/202137-116-121-119N/A
9/30/202166-72-107-105N/A
6/30/202166-64-103-100N/A
3/31/202167-612325N/A
12/31/202068-6535N/A
9/30/202092-54-9-7N/A
6/30/202085-63-8-5N/A
3/31/202078-76-154-151N/A
12/31/201927-133-144-140N/A
9/30/201961-99-144-140N/A
6/30/201962-99-126-122N/A
3/31/201975-83-105-100N/A
12/31/201860-85-79-76N/A
9/30/201875-52-28-25N/A
6/30/201887-39-27-25N/A
3/31/201874-50173175N/A
12/31/201772-43169170N/A
9/30/201751-58N/A150N/A
6/30/201730-62N/A142N/A
3/31/201724-51N/A-16N/A
12/31/201615-59N/A-2N/A
9/30/201611-57N/A-12N/A
6/30/20169-57N/A-6N/A
3/31/20168-50N/A-28N/A
12/31/20158-42N/A-27N/A
9/30/20158-36N/A-24N/A
6/30/20158-26N/A30N/A
3/31/20156-24N/A31N/A
12/31/20145-35N/A32N/A
12/31/20131-19N/A-8N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 6C1 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 6C1 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 6C1 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 6C1's revenue is expected to decline over the next 3 years (-13.3% per year).

High Growth Revenue: 6C1's revenue is forecast to decline over the next 3 years (-13.3% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 6C1 is forecast to be unprofitable in 3 years.


Discover growth companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.